Obermatt
See Similar Stocks →

C4 Therapeutics

NSQ:CCCC · US12529R1077
BiotechnologySmall

360

17
Profit price54
Cash yield1
Price/Sales41
EV / Gross Profit29
Price/Book46
Return on Capital54
Cash Return on Capital50
Return on Equity53
EBIT Margin1
Gross Profitability45
Accruals29
Owner Earnings Margin19
Sales growth15
Profit growth51
Reinvestment71
Price momentum79
Debt load31
Refinancing44
Debt Payback1
Liquidity32
Analyst ratings80
Opinion Changes50
Price Target Upside89
Market mood39
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

C4 Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees107
Websitec4therapeutics.com
ISINUS12529R1077
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyInflammationHematologyImmunologyGeneticsOncologyCentral Nervous SystemHealth Care

Description

C4 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transfor…

Analysis

Middle-of-the-road

C4 Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
34
2026

All-time high

34

Jun 2026

All-time low

23

Mar 2026

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
41
—
—
—
Price/Earnings
33
—
—
—
Price/Book
46
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
36
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare C4 Therapeutics with its peers
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Avidity Biosciences
NMQ:RNA
28
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ALX Oncology Holdings
NSQ:ALXO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ArriVent BioPharma
NMQ:AVBP
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →